JME Group, Inc. is a privately held, biotechnology company founded on March 2014 in New Jersey, U.S.The company embarked on a project to develop and commercialize a safer and affordable enzyme replacement therapy (ERT) for metabolic and lysosomal storage diseases (a group of rare (orphan) diseases deficient in lysosomal enzymes) via oral administration (hence Oral-ERT) using plant-derived recombinant human enzymes or proteins plus natural non-GMO plant products for improvement of human and animal health. The first enzyme in the pipeline using this platform is a recombinant human lysosomal acid alpha-glucosidase (GAA) or acid maltase produced in tobacco seeds for the treatment of acid maltase deficiency (AMD or POMPE disease).